Skip to main content
. 2023 Jul 4;1(4):238–252. doi: 10.1016/j.cpt.2023.06.004

Figure 1.

Figure 1

Layout of this study, including the parameters investigated and databases or tools used for the analyses. CNV: Copy number variation; CPTAC: Clinical Proteomic Tumor Analysis Consortium; DFS: Disease-free survival; GEPIA 2.0: Gene Expression Profiling Interactive Analysis 2; GO: Gene Ontology; GSCA: Gene Set Cancer Analysis; GTEx: Genotype-tissue expression; KEGG: Kyoto Encyclopedia of Genes and Genomes; LUAD: Lung adenocarcinoma; NPM3: Nucleophosmin/nucleoplasmin 3; OS: Overall survival; RT-qPCR: Real-time quantitative polymerase chain reaction; TCGA: The Cancer Genome Atlas; TIMER 2.0: Tumor immune estimation resource, version 2.